CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-11 | Sibold William John President and CEO | Grant or award · Performance Restricted Stock Units | +50,000 | 50,000 | ||
| 2023-06-15 | BAKER BROS. ADVISORS LP Director | Grant or award | +4,792 | 153,613 | ||
| 2023-06-15 | BAKER BROS. ADVISORS LP Director | Grant or award | +4,792 | 1,401,084 | ||
| 2023-06-15 | Levy Richard S Director | Grant or award | +1,198 | 10,298 | ||
| 2023-06-15 | CRAVES FRED B Director | Grant or award | +1,198 | 362,556 | ||
| 2023-06-15 | Daly James M Director | Grant or award | +1,198 | 1,198 | ||
| 2023-06-15 | BATE KENNETH Director | Grant or award | +1,198 | 1,198 | ||
| 2023-03-01 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +5,000 | $87.92 | $440K | 10,667 |
| 2023-03-01 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,928 | $273.44 | $527K | 8,739 |
| 2023-03-01 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,672 | $274.57 | $459K | 7,067 |
| 2023-03-01 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,300 | $275.53 | $358K | 5,767 |
| 2023-03-01 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −100 | $276.19 | $28K | 5,667 |
| 2023-03-01 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −5,000 | 25,000 | ||
| 2023-02-28 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +5,000 | $87.92 | $440K | 10,667 |
| 2023-02-28 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −900 | $271.03 | $244K | 9,767 |
| 2023-02-28 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −4,100 | $272.30 | $1.1M | 5,667 |
| 2023-02-28 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −5,000 | 30,000 | ||
| 2023-01-30 | CRAVES FRED B Director | Gift | −3,557 | 57,062 | ||
| 2023-01-17 | Levy Richard S Director | Option exercise | +12,489 | $105.08 | $1.3M | 21,589 |
| 2023-01-17 | Levy Richard S Director | Option exercise | +10,000 | $100.45 | $1.0M | 31,589 |
Page 47 of 82 · 1,629 trades